Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 6% – Here’s Why

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)’s share price fell 6% during mid-day trading on Thursday. The stock traded as low as $11.16 and last traded at $11.2190. Approximately 1,012,746 shares changed hands during trading, a decline of 24% from the average session volume of 1,336,210 shares. The stock had previously closed at $11.93.

Key Stories Impacting Monte Rosa Therapeutics

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: Positive Phase 1 biomarker data: In the GFORCE-1 study of obese subjects with elevated cardiovascular risk, MRT-8102 produced robust and sustained NEK7 degradation at all tested doses. Biomarkers linked to plaque inflammation, thrombosis and systemic inflammation—including HMGB1, calprotectin, S100A12, SAA and IL-1β—fell to levels comparable with those seen in healthy volunteers. Monte Rosa Phase 1 GFORCE-1 results
• Positive Sentiment: Favorable safety profile and development plans: Four weeks of treatment and four weeks of follow-up produced no serious adverse events, adverse-event rates similar to placebo, and no evidence of increased infection risk. Monte Rosa plans Phase 2 studies in coronary artery disease, gout and hidradenitis suppurativa, expanding MRT-8102’s potential commercial applications. Monte Rosa plans Phase 2 trials
• Positive Sentiment: Analyst endorsement: HC Wainwright began coverage with a Buy rating and a $25 price target, implying substantial upside from the stock’s recent trading level. HC Wainwright coverage
• Neutral Sentiment: Early-stage evidence remains the key limitation: The results are biomarker-based Phase 1 findings, not proof that MRT-8102 reduces cardiovascular events or improves clinical outcomes. Investors will likely focus on the upcoming Phase 2 trials and details discussed during the company’s special call. Monte Rosa special call transcript
• Neutral Sentiment: Much of the catalyst was anticipated: Shares had gained ahead of the clinical-trial review, so the subsequent weakness may reflect profit-taking or a “sell-the-news” reaction despite the positive data. Monte Rosa shares ahead of trial review

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on GLUE. HC Wainwright assumed coverage on shares of Monte Rosa Therapeutics in a report on Thursday. They issued a “buy” rating and a $25.00 target price for the company. Weiss Ratings lowered Monte Rosa Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, August 11th. Wedbush restated an “outperform” rating and issued a $27.00 price target on shares of Monte Rosa Therapeutics in a research report on Wednesday, September 9th. Guggenheim reaffirmed a “buy” rating and set a $28.00 price objective on shares of Monte Rosa Therapeutics in a research note on Tuesday, August 25th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $28.00.

Monte Rosa Therapeutics Price Performance

The firm’s 50-day simple moving average is $15.11 and its two-hundred day simple moving average is $17.79. The company has a market capitalization of $961.87 million, a price-to-earnings ratio of -6.41 and a beta of 1.50.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 43.31%. The company had revenue of $8.97 million during the quarter, compared to analysts’ expectations of $12.91 million. On average, analysts expect that Monte Rosa Therapeutics, Inc. will post -1.04 EPS for the current fiscal year.

Insider Buying and Selling at Monte Rosa Therapeutics

In related news, insider Sharon Townson sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $23.31, for a total value of $139,860.00. Following the completion of the transaction, the insider directly owned 67,845 shares of the company’s stock, valued at $1,581,466.95. This trade represents a 8.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Monte Rosa Therapeutics

A number of institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Monte Rosa Therapeutics in the second quarter valued at $165,603,000. Jupiter Topco LLC purchased a new stake in shares of Monte Rosa Therapeutics in the 2nd quarter worth about $25,965,000. Opaleye Management Inc. acquired a new stake in Monte Rosa Therapeutics in the 2nd quarter valued at about $18,029,000. Janus Henderson Group PLC acquired a new stake in Monte Rosa Therapeutics in the 1st quarter valued at about $11,294,000. Finally, Nantahala Capital Management LLC acquired a new stake in Monte Rosa Therapeutics in the 2nd quarter valued at about $15,778,231. 79.96% of the stock is currently owned by hedge funds and other institutional investors.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company developing small-molecule medicines designed to selectively eliminate disease-causing proteins. The company uses its proprietary Tunable Molecular Glue (TME) platform to identify molecular glue degraders that redirect the cell’s natural protein-degradation machinery toward specific therapeutic targets.

Monte Rosa’s research and development programs address areas including autoimmune and inflammatory diseases, as well as cancer.